Athira Pharma Inc. failed to disclose problems about research the company’s president and CEO conducted while pursuing her graduate degree, according to three new securities suits filed in federal court in Washington state.
The biopharmaceutical company didn’t tell investors that the research included manipulated data, the three complaints filed in the U.S. District Court for the Western District of Washington allege. Two of the suits center on statements connected to Athira Pharma’s September 2020 initial public offering.
Reports surfaced June 17 alleging several papers CEO Leen Kawas published while completing coursework included altered images. Athira Pharma’s board placed Kawas on ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.